Compare GOLF & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOLF | ABCL |
|---|---|---|
| Founded | 1910 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 2016 | 2020 |
| Metric | GOLF | ABCL |
|---|---|---|
| Price | $78.03 | $12.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $99.67 | $16.82 |
| AVG Volume (30 Days) | 327.1K | ★ 4.9M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $1,633,721,000.00 | $75,128,000.00 |
| Revenue This Year | $4.42 | N/A |
| Revenue Next Year | $3.22 | $7.12 |
| P/E Ratio | $23.64 | ★ N/A |
| Revenue Growth | 4.71 | ★ 160.56 |
| 52 Week Low | $75.19 | $2.75 |
| 52 Week High | $119.65 | $14.98 |
| Indicator | GOLF | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 29.95 | 49.45 |
| Support Level | N/A | $11.78 |
| Resistance Level | $92.26 | $12.88 |
| Average True Range (ATR) | 2.26 | 0.80 |
| MACD | -0.07 | -0.25 |
| Stochastic Oscillator | 3.26 | 16.50 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.